Profile data is unavailable for this security.
About the company
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Company’s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.
- Revenue in USD (TTM)176.58m
- Net income in USD-103.71m
- Incorporated2021
- Employees626.00
- LocationProcept Biorobotics Corp150 Baytech DriveSAN JOSE 95134United StatesUSA
- Phone+1 (650) 232-9832
- Fax+1 (302) 636-5454
- Websitehttps://www.procept-biorobotics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UFP Technologies Inc | 417.47m | 49.55m | 2.59bn | 3.09k | 52.72 | 8.36 | 42.26 | 6.21 | 6.41 | 6.41 | 54.02 | 40.42 | 1.02 | 4.26 | 6.68 | 134,971.50 | 12.08 | 9.69 | 13.85 | 10.95 | 28.02 | 26.33 | 11.87 | 10.14 | 1.63 | 21.63 | 0.1024 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
10X Genomics Inc | 631.73m | -239.78m | 2.66bn | 1.26k | -- | 3.67 | -- | 4.21 | -2.02 | -2.02 | 5.31 | 6.01 | 0.6583 | 2.59 | 7.06 | 501,773.60 | -24.99 | -25.52 | -28.04 | -29.05 | 64.70 | 75.88 | -37.96 | -48.53 | 4.42 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
LivaNova PLC | 1.21bn | -16.59m | 2.77bn | 2.90k | -- | 2.23 | 92.45 | 2.29 | -0.3133 | -0.3133 | 22.29 | 22.88 | 0.5046 | 2.52 | 6.26 | 417,149.00 | -0.6876 | -6.01 | -0.7843 | -7.42 | 67.64 | 66.99 | -1.36 | -13.56 | 2.94 | 2.19 | 0.3347 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
Tandem Diabetes Care Inc | 796.00m | -136.49m | 2.79bn | 2.40k | -- | 11.93 | -- | 3.51 | -2.09 | -2.09 | 12.21 | 3.57 | 0.8449 | 2.62 | 8.09 | 331,667.50 | -14.49 | -10.08 | -18.58 | -12.23 | 49.06 | 51.77 | -17.15 | -11.59 | 2.38 | -- | 0.598 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
Quidelortho Corp | 2.83bn | -1.86bn | 3.11bn | 7.10k | -- | 0.9775 | -- | 1.10 | -27.79 | -27.79 | 42.35 | 47.30 | 0.372 | 2.58 | 9.15 | 399,239.40 | -24.40 | 11.34 | -27.51 | 12.91 | 47.89 | 62.71 | -65.60 | 20.93 | 0.7929 | 0.7895 | 0.4469 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
Envista Holdings Corp | 2.53bn | -1.32bn | 3.30bn | 12.80k | -- | 1.11 | -- | 1.30 | -7.70 | -7.70 | 14.64 | 17.32 | 0.4207 | 4.08 | 6.37 | 197,937.50 | -21.98 | 1.94 | -26.29 | 2.34 | 54.89 | 57.65 | -52.25 | 5.29 | 1.90 | 3.92 | 0.3357 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
Axonics Inc | 408.81m | -1.71m | 3.51bn | 797.00 | -- | 5.45 | 323.67 | 8.59 | -0.0291 | -0.0291 | 8.11 | 12.61 | 0.5856 | 1.12 | 7.81 | 512,934.80 | -0.2451 | -12.67 | -0.2618 | -13.76 | 75.89 | 70.04 | -0.4185 | -29.68 | 7.11 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
Evolent Health Inc | 2.35bn | -106.20m | 3.59bn | 4.70k | -- | 3.36 | 234.28 | 1.52 | -0.9367 | -0.9367 | 20.71 | 10.79 | 0.9191 | -- | 6.55 | 500,823.00 | -2.91 | -9.60 | -3.63 | -12.59 | 18.57 | 24.50 | -3.16 | -13.66 | -- | -0.2382 | 0.326 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
Neogen Corp | 924.22m | -9.42m | 3.74bn | 2.92k | -- | 1.19 | 34.82 | 4.04 | -0.0435 | -0.0435 | 4.27 | 14.51 | 0.203 | 2.85 | 5.67 | 316,839.90 | -0.207 | 1.38 | -0.214 | 1.44 | 50.19 | 48.23 | -1.02 | 4.31 | 2.59 | 1.19 | 0.2208 | 0.00 | 12.37 | 17.41 | 58.81 | -- | 50.02 | -- |
Haemonetics Corporation | 1.33bn | 114.89m | 3.87bn | 3.66k | 33.87 | 4.27 | 17.73 | 2.90 | 2.23 | 2.23 | 25.92 | 17.70 | 0.5924 | 1.87 | 7.05 | 364,751.20 | 5.10 | 5.02 | 5.74 | 6.07 | 53.58 | 51.74 | 8.61 | 8.11 | 2.33 | 60.20 | 0.5747 | 0.00 | 12.01 | 6.23 | 1.87 | 16.40 | -11.04 | -- |
Procept Biorobotics Corp | 176.58m | -103.71m | 4.27bn | 626.00 | -- | 17.10 | -- | 24.16 | -2.06 | -2.06 | 3.50 | 4.85 | 0.546 | 1.85 | 3.83 | 282,068.70 | -32.07 | -- | -36.52 | -- | 54.73 | -- | -58.73 | -- | 6.49 | -- | 0.1696 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
Integer Holdings Corp | 1.67bn | 105.37m | 4.30bn | 10.50k | 42.11 | 2.77 | 20.59 | 2.58 | 3.05 | 3.05 | 48.27 | 46.34 | 0.5574 | 4.88 | 5.10 | 158,938.20 | 3.52 | 3.28 | 3.78 | 3.53 | 26.77 | 26.94 | 6.31 | 6.40 | 1.96 | 3.67 | 0.4215 | 0.00 | 16.03 | 5.62 | 38.71 | 9.33 | 21.71 | -- |
ICU Medical Inc | 2.30bn | -70.79m | 4.30bn | 14.00k | -- | 2.11 | 27.45 | 1.87 | -2.92 | -2.92 | 94.90 | 83.43 | 0.5267 | 2.13 | 14.68 | 164,591.20 | -1.62 | 1.46 | -1.83 | 1.65 | 32.47 | 34.11 | -3.07 | 2.23 | 1.08 | 0.5555 | 0.4412 | 0.00 | -0.9154 | 10.04 | 60.08 | -- | -1.45 | -- |
TransMedics Group Inc | 358.76m | 3.00m | 5.20bn | 584.00 | 3,779.93 | 27.36 | 299.04 | 14.50 | 0.0413 | 0.0413 | 10.61 | 5.70 | 0.4952 | 3.56 | 5.58 | 614,313.40 | 0.4141 | -16.08 | 0.4403 | -17.95 | 60.71 | 65.37 | 0.8362 | -40.47 | 8.48 | -- | 0.7278 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
DENTSPLY SIRONA Inc | 3.90bn | -185.00m | 5.41bn | 15.00k | -- | 1.77 | 33.02 | 1.39 | -0.8698 | -0.8698 | 18.65 | 15.12 | 0.5356 | 2.94 | 6.18 | 259,733.30 | -2.49 | -1.14 | -3.03 | -1.32 | 52.23 | 53.65 | -4.65 | -2.51 | 0.8692 | 3.65 | 0.4066 | -- | 1.10 | -0.1071 | 86.11 | -- | -4.54 | 9.86 |
Merit Medical Systems Inc | 1.30bn | 117.43m | 5.75bn | 6.95k | 49.20 | 4.48 | 27.00 | 4.42 | 2.01 | 2.01 | 22.24 | 22.04 | 0.6183 | 2.30 | 7.36 | 187,231.10 | 5.58 | 2.45 | 6.13 | 2.77 | 46.54 | 44.50 | 9.02 | 3.91 | 4.64 | 17.52 | 0.3846 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 7.23m | 13.91% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 4.59m | 8.84% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 3.13m | 6.02% |
AllianceBernstein LPas of 30 Jun 2024 | 1.81m | 3.48% |
T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 1.75m | 3.36% |
Champlain Investment Partners LLCas of 30 Jun 2024 | 1.37m | 2.63% |
Loomis, Sayles & Co. LPas of 30 Jun 2024 | 1.26m | 2.43% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.11m | 2.14% |
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 1.08m | 2.09% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.02m | 1.97% |